EGFR and lung cancer: In the second study, a large retrospective single center series from Canada, comprising 712 never smoking lung cancer patients (adenocarcinoma histology– 87%), 515 of whom had tumor tissue available for molecular analysis, Korpanty et al. [1] reported EGFR, KRAS, TP53, ERBB2, BRAF and PIK3CA mutation and ALK rearrangement in 52.2%, 2.3%, 1.4%, 1,0%, 0.4%, 0.4% and 7.6% of patients, respectively, using MassARRAY technology (Sequenom, San Diego, CA) or MiSeq (Illumina, San Diego, CA) NGS personal genomics platforms as testing methods.